Research in the Schizophrenia Division covers everything from basic science experiments to research on how treatments and life experiences affect illness outcomes. This research aims to understand the causes and development of schizophrenia, and extends our understanding of illness effects and treatments. As some examples, we study how new and promising treatments work, the impact of substance use in people with schizophrenia, and what factors in our communities and families affect the illness.
Our clinical program has 167 inpatient beds and approximately 4,000 outpatients with schizophrenia, with 190,000 patient visits in the last year.
Our core research faculty has diverse interests and expertise, including illness effects and outcomes, clinical treatment trials, psychopharmacology, genetics and pharmacogenetics, clinical electrophysiology, structural and functional imaging, and basic biochemistry, cell biology and molecular biology. Together, we have created a research program that exemplifies a modern, translational approach to research on schizophrenia with the aim of better understanding and treating schizophrenia. Our faculty and areas of expertise are listed below.
First Episode Psychosis: Dr. Ofer Agid
Genetics (including clinical, epigenetics and molecular): Dr. Anne Bassett; Dr Vincenzo DeLuca; Dr. Jim Kennedy; Dr. Daniel Mueller; Dr Arturas Petronis and Dr. Albert Wong
Imaging: Dr. Ariel Graff; Dr. Romina Mizrahi; and Dr. Aristotle Voineskos
Metabolic and Medical Monitoring: Dr. Tony Cohn
Psychopharmacology and Treatment Resistance: Dr. Gary Remington
Recovery and Rehabilitation: Dr. Sean Kidd
Smoking and Substance Use: Dr. Tony George